|
||
About 70% of Early-stage Breast Cancer Patients may Avoid Agony of Chemotherapy: StudyThousands of breast cancer patients are likely to benefit under a new precision medicine approach | ||
Mumbai, Maharashtra, India
Breakthrough finding by the landmark Trial Assigning Individualized Options for Treatment (TAILORx) demonstrates the Oncotype DX Breast Recurrence Score® Test definitively identifies the 70% of women with early-stage breast cancer who receive no benefit from chemotherapy, and the 30% of women for whom chemotherapy benefit can be life-saving.
|
||
|
|||||
| |||||